PMMI ProSource – Start Your Search
Check out our packaging and processing solutions finder, PMMI ProSource.

Digital Display Labels Set to Transform the Clinical Supply Chain

At the AIPIA & AWA Smart Packaging Congress, Merck and Johnson & Johnson discuss digital display labels, a promising technology poised to enhance clinical supply chains.

A prototype of a digital display label attached to a vial containing a drug for a clinical trial.
A prototype of a digital display label attached to a vial containing a drug for a clinical trial.

One of the most exciting presentations at this year’s AIPIA & AWA Smart Packaging Congress was a panel featuring Matt Bolton, director of global clinical supply technology innovation from Merck, and Pieter Piron, manufacturing science and technology engineer for Johnson & Johnson Innovative Medicine, who unveiled a collaborative effort to modernize the pharmaceutical sector using digital display labels. This technology, though not new, is being repurposed to address the unique challenges faced in clinical trials, offering a glimpse into a more efficient and adaptable future.

The pharmaceutical industry, often characterized by its stringent regulations and complex supply chains, is ripe for transformation. Bolton and Piron emphasized the critical role of clinical trials in drug development, where speed and accuracy are paramount. Traditional paper labels, with their static content and lengthy production times, have long been a bottleneck. The introduction of digital display labels promises to alleviate these issues by allowing real-time updates and multilingual capabilities, thus reducing waste and improving patient compliance.

The collaboration between Merck and Johnson & Johnson is notable not only for its potential impact, but also for its rarity. In an industry where competition is fierce, the partnership underscores a shared vision for innovation that transcends corporate boundaries. This joint effort, facilitated by the Clinical Supply Leadership Forum, highlights the importance of collaboration in tackling industry-wide challenges.

Digital display labels offer several advantages over traditional methods. They enable dynamic content updates, which are crucial in clinical trials where information such as expiry dates and protocol numbers can change rapidly. This flexibility is particularly beneficial in Phase One trials, where speed is essential to move from concept to patient delivery. Furthermore, the ability to customize labels for different languages and regulatory requirements streamlines the global distribution process, a significant advantage in today's interconnected world.

Despite the promise of digital display labels, challenges remain. The technology's cost is currently higher than that of paper labels, and its integration into existing supply chains requires careful planning and investment. However, the potential benefits in terms of reduced waste, improved compliance, and faster time-to-market make a compelling case for adoption.

The potential for digital display labels extends beyond immediate logistical improvements. By integrating additional features such as temperature and light sensors, these labels could provide real-time data on the environmental conditions of pharmaceuticals, ensuring that they remain within safe parameters throughout their journey. This capability could significantly enhance the reliability of clinical trials, where maintaining the integrity of drug samples is crucial.

New e-book on Flexible Packaging
In this e-book, you’ll learn key considerations for vertical and horizontal f/f/s and how to choose between premade bags and an f/f/s system. Plus, discover the pitfalls to avoid on bagging machinery projects.
Read More
New e-book on Flexible Packaging
Connected Workforce Report
Discover how connected workforce technologies and automation can bridge the skills gap in our latest report. Explore actionable insights and innovative solutions.
Read More
Connected Workforce Report